N/A
N=31
Evaluation of Novel Cone-Beam CT for Guidance and Adaptation of Precision Radiotherapy
Lung Cancer · Liver Cancer · Breast Cancer · Other Cancer
Bottom Line
View on ClinicalTrials.gov: NCT05176860 ↗Enrolled (actual)
31
Serious AEs
0.0%
Results posted
May 2026
Primary outcome: Primary: CBCT Image Quality - Artifact Index — 20.2; 32.9; 59.2; 17.3 HU
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- CBCT Imaging (Device)
- Age
- Adult, Older Adult · 19+ yrs
- Sex
- All
- Sponsor
- Varian, a Siemens Healthineers Company
- Primary completion
- Jul 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY CBCT Image Quality - Artifact Index |
20.2; 32.9; 59.2; 17.3 | — |
| PRIMARY CBCT Image Quality - Image Nonuniformity |
0.1; 0.25; 0.25; 0.05 | — |
| PRIMARY CBCT Image Quality - Contrast |
134.1; 129.7; 126.8; 142.3 | — |
| PRIMARY CBCT Image Quality - Contrast to Noise Ratio |
6.64; 4.13; 5.10 | — |
| PRIMARY CBCT Image Quality - HU Similarity to CT Simulation |
-12.1; -31.4; 6.7; -14.0; 85.0; -33.0 | — |
| SECONDARY Dosimetry Calculations - Gamma Pass Rate |
96.7; 93.3; 89.9; 85.4; 70.2; 61.6 | — |
| SECONDARY Dosimetry Calculations - Target DVH Volume Metrics |
0.1; 0.0; 0.3; 0.0; 1.5; 0.2 | — |
| SECONDARY Dosimetry Calculations - Target DVH Dose Metrics |
0.5; 0.0; 1.0; 0.5; 2.2; 1.5 | — |
| SECONDARY Dosimetry Calculations - Breast OAR DVH Metrics |
-1.4; -2.7; 1.1; 2.9; 0.1; 0.5 | — |
| SECONDARY Dosimetry Calculations - Lung OAR DVH Metrics |
-0.3; -0.1; 0.1; -0.2; -0.4; -0.1 | — |
| SECONDARY Dosimetry Calculations - Abdomen OAR DVH Metrics |
0.7; -0.8; -0.2; -0.6; -0.1; 0.0 | — |
Summary
This is a feasibility study investigating the image quality of a new, high-performance cone beam CT (CBCT) used for on-couch imaging during radiotherapy treatments.
Eligibility Criteria
Inclusion Criteria
- Subject is scheduled for treatment on one of the five TrueBeam platforms at the NS Health QE2 site.
- Subject is receiving radiation therapy using a breath-hold technique (for example, lung, liver and left breast cancers).
Exclusion Criteria
- Patient is pregnant or has plans for pregnancy during the period of treatment.
- Patient is unwilling to consent to participating to the study, or for whom informed consent is not possible.
Data sourced from ClinicalTrials.gov (NCT05176860). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.